Korean companies bid to break AZ’s monopoly with FcRN drug

By Son, Hyung-Min | translator Kim, Jung-Ju

23.11.27 12:02:15

가나다라 0

HanAll in Phase III trial for batoclimab…Phase I trial also ongoing for a new drug candidate Handok introduces Vyvgart from Argenx…for exclusive supply in Korea

HanAll in Phase III trial for batoclimab…Phase I trial also ongoing for a new drug candidate

New FcRN drug to compete with C5 complement inhibitors like Ultromiris

With new FcRn antibody drugs secured by Korean pharmaceutical companies demonstrating efficacy in myasthenia gravis, these new FcRn antibody drugs are expected to rise as a competitor to C5 complement inhibitors such as AstraZeneca’s Ultromiris and Soliris that currently occupy the market in Korea.

to industry sources on the 27th, Handok is preparing to apply for marketing authorization of its new FcRn antibody drug Vyvgart (efgartigimod). The company had signed an agreement with the Belgian company Argenx for

Son, Hyung-Min(shm@dailypharm.com)

If you want to see the full article, please JOIN US (click)